Polyethylene glycol microspheres loaded with irinotecan for arterially directed embolic therapy of metastatic liver cancer

Fecha de publicación: 15/09/2017

Autores de IIS La Fe

Fernando Gómez Muñoz

Autor

Participantes ajenos a IIS La Fe

Fiorentini, G
Carandina, R
Sarti, D
Nardella, M
Zoras, O
Guadagni, S
Inchingolo, R
Nestola, M
Felicioli, A
Navarro, DB
Aliberti, C

Abstract

AIM To study tumor response, and tolerability of arterially directed embolic therapy (ADET) with polyethylene glycol embolics loaded with irinotecan for the treatment of colorectal cancer liver metastases (CRC-LM). Secondary objectives were to monitor quality of life, time to progression and survival of patients. METHODS Patients were included in the study if they were affected by CRC-LM, refractory to systemic chemotherapy, treated with ADET using polyethylene glycol embolics, and had liver involvement < 50%. Tumor response, performance status (PS), tumor marker antigens, and quality of life (QoL) were monitored at 1, 3 and 6 mo after ADET. QoL was assessed with the Palliative Performance Scale (PPS). RESULTS We treated 50 consecutive CRC-LM patients with ADET using polyethylene glycol embolics. Their tumor response one month after ADET was: 28% of complete response (CR), 48% of partial response (PR), 8% stable disease (SD), and 16% of progression. Tumor response 3 mo after ADET was CR 24%, PR 38%, SD 19% and progression disease (PD) 19%. Tumor response 6 mo after ADET was CR 18%, PR 44%, SD 21% and PD 18%. QoL was 90% PPS at each time point. Median time to progression for patients who progressed was 2.5 mo (range 0.8-6). Median follow-up was 14 mo (0.8-25 range). ADETs were performed with no complications. Observed side effects (mild or moderate intensity) were: Pain in 32% of patients, increase of transaminase levels in 20% and fever in 14%, whereas 30% of patients did not complain any adverse event. CONCLUSION The treatment of unresectable CRC-LM with ADET using polyethylene glycol microspheres loaded with irinotecan was effective in tumor response and resulted in mild toxicity, and good QoL.

Datos de la publicación

ISSN/ISSNe:: 1948-5204, 1948-5204
Tipo:: Article
Páginas:: 379-384
DOI:: 10.4251/wjgo.v9.i9.379

Documentos

No hay documentos

Métricas

Filiaciones

Fiorentini, G:: Azienda Osped Osped Riuniti Marche Nord, Onco Hematol Dept, Via Lombroso 1, I-61122 Pesaro, Italy
Carandina, R:: Inst Res & Treatment Canc, Oncol Inst Veneto, Oncol Radiodiag Dept, I-35128 Padua, Italy
Sarti, D:: Azienda Osped Osped Riuniti Marche Nord, Onco Hematol Dept, Via Lombroso 1, I-61122 Pesaro, Italy
Nardella, M:: Osped Madonna Grazie, Diagnost & Interventt Radiol Dept, I-75100 Matera, Italy
Zoras, O:: Univ Crete, Surg Oncol, Voutes Campus, Iraklion GR-71003, Greece
Guadagni, S:: Univ Laquila, Dept Appl Clin Sci & Biotechnol, Sect Gen Surg, I-67100 Laquila, Italy
Inchingolo, R:: Osped Madonna Grazie, Diagnost & Interventt Radiol Dept, I-75100 Matera, Italy
Nestola, M:: Osped Madonna Grazie, Diagnost & Interventt Radiol Dept, I-75100 Matera, Italy
Felicioli, A:: Azienda Osped Osped Riuniti Marche Nord, Diagnost & Interventt Radiol Dept, I-61122 Pesaro, Italy
Navarro, DB:: Hosp Clin Barcelona, Intervent Radiol Dept, E-08036 Barcelona, Spain
Gomez, FM:: Hosp Univ & Politecn La Fe, Diagnost Images & Vasc & Itervent Radiol Dept, E-46026 Valencia, Spain
Aliberti, C:: Inst Res & Treatment Canc, Oncol Inst Veneto, Oncol Radiodiag Dept, I-35128 Padua, Italy

Keywords

Liver metastases; Arterially directed embolic therapy; Colorectal cancer; Polyethylene glycol embolics; Irinotecan

Campos de estudio

Proyectos asociados

ENSAYO CLÍNICO PROSPECTIVO Y RANDOMIZADO SOBRE EL USO DE LA RADIOEMBOLIZACIÓN TRANSARTERIAL CON ITRIO 90 (THERASPHERE®) FRENTE AL TRATAMIENTO HABITUAL (SORAFENIB), EN EL TRATAMIENTO DE PACIENTES CON CARCINOMA HEPATOCELULAR EN ESTADIO AVANZADO Y TROMBOSIS PORTAL ASOCIADA.

Investigador Principal: DANIEL PÉREZ ENGUIX

TS-104

Cita

Cita Bibliográfica